Skip to content

Can you get a GLP-1 for PCOS? What labels and insurers say

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

No GLP-1 drug is FDA-approved to treat polycystic ovary syndrome (PCOS). People with PCOS can still be prescribed one, and sometimes get it covered, when they also meet a use the label does cover, such as weight management or type 2 diabetes.

What PCOS is

The National Institute of Child Health and Human Development (NICHD) describes PCOS as a set of symptoms tied to a hormonal imbalance [1], and the most common cause of infertility caused by not ovulating [2]. The HHS Office on Women’s Health says between 5% and 10% of women aged 15 to 44 have it [3], and that more than half of women with PCOS will have diabetes or prediabetes before age 40 [4].

Weight matters in PCOS care. NICHD says that for people with PCOS who have overweight or obesity, losing a small amount of weight and being more active can ease many symptoms and related health problems [5]. The Office on Women’s Health says even a 10% weight loss can help make periods more regular and improve the chance of pregnancy [6].

Using medicines without a PCOS approval is not new. NICHD notes that metformin is not FDA-approved to treat PCOS but may help reduce symptoms [7].

What the GLP-1 labels cover

Here is what each label approves, in short form; PCOS is not on any of them [8]:

Medicine FDA-approved uses (short form)
Wegovy Weight management in adults with obesity, or with overweight plus at least one weight-related condition [8]
Zepbound The same weight-management wording [9], plus moderate to severe sleep apnea in adults with obesity [10]
Foundayo The same weight-management wording [11]
Ozempic Blood sugar control in adults with type 2 diabetes [12]
Mounjaro Blood sugar control in type 2 diabetes, for adults and children 10 and older [13]

The weight-management indications do not name which weight-related conditions count. That gap is where insurers write their own lists.

How coverage works if you have PCOS

Insurers pay for approved uses, not for PCOS as a diagnosis on its own. BlueCross BlueShield of South Carolina, for example, says every GLP-1 needs prior authorization and is authorized only for FDA-approved uses [14]. The federal employee Blue plan says prior approval checks that you are using the drug to treat something it covers [15].

On top of that, plans set their own thresholds. Blue Shield of California says, depending on the plan, coverage for a new prescription may be limited to a BMI of 40 or more, or open at BMI 30, or at BMI 27 with certain conditions [16]. Many plans leave weight-loss drugs out entirely: Aetna says many of its plans exclude them [17], and it tells employers they can choose to include or exclude GLP-1 coverage for weight management [18].

In practice, a request that gives PCOS as the reason asks the plan to pay for a use no label carries. A request under obesity, or overweight with a weight-related condition, or under type 2 diabetes if you have it, matches an approved use. Whether your plan counts PCOS as one of its weight-related conditions depends on its written criteria. Ask your prescriber to check them, and see how prior authorization works and coverage by insurer.

Before you start: birth control and pregnancy

Two label points matter for many people with PCOS, who may use birth control pills or be planning a pregnancy:

  • Zepbound’s label says it can make birth control pills less effective, and advises switching to a non-pill method or adding a barrier method for 4 weeks after starting and 4 weeks after each dose increase [19].
  • Wegovy’s label says to stop it at least 2 months before a planned pregnancy [20].
  • Zepbound’s label says weight loss is not recommended during pregnancy and the drug should be stopped once a pregnancy is recognized [21].

Talk these through with your prescriber before you start. If your plan says no, cash prices for the drugs approved for weight management are in our price comparison and GLP-1 cost without insurance.

Research on GLP-1 drugs in women with PCOS is still thin. A 2026 systematic review pooled 11 randomized trials and found that a GLP-1 drug added to other treatment lowered BMI by 1.38 points more than the comparison groups, a result it rated as low certainty [22]. The authors called the weight loss modest and short term, and said any benefit for metabolic, reproductive or psychological outcomes is still uncertain because the data are of low quality [23].

Sources

  1. PCOS is a set of symptoms related to a hormonal imbalance. nichd.nih.gov, read Sep 27, 2026.
  2. PCOS is the most common cause of anovulatory infertility, meaning that the infertility results from the absence of ovulation. nichd.nih.gov, read Sep 27, 2026.
  3. Between 5% and 10% of women between 15 and 44, or during the years you can have children, have PCOS. womenshealth.gov, read Sep 27, 2026.
  4. More than half of women with PCOS will have diabetes or prediabetes (glucose intolerance) before the age of 40. womenshealth.gov, read Sep 27, 2026.
  5. Research shows that, if a person with PCOS has overweight or obesity, losing a small amount of weight and being more physically active can minimize many PCOS symptoms and related health issues, especially cardiovascular risks. nichd.nih.gov, read Sep 27, 2026.
  6. Even a 10% loss in body weight (for example, a 150-pound woman losing 15 pounds) can help make your menstrual cycle more regular and improve your chances of getting pregnant. womenshealth.gov, read Sep 27, 2026.
  7. Insulin-sensitizing medications, such as metformin, are not FDA approved to treat PCOS, but may help reduce symptoms. nichd.nih.gov, read Sep 27, 2026.
  8. adults with overweight in the presence of at least one weight-related comorbid condition. dailymed.nlm.nih.gov, read Sep 27, 2026.
  9. to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. dailymed.nlm.nih.gov, read Sep 27, 2026.
  10. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. dailymed.nlm.nih.gov, read Sep 27, 2026.
  11. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. (1) dailymed.nlm.nih.gov, read Sep 27, 2026.
  12. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. dailymed.nlm.nih.gov, read Sep 27, 2026.
  13. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. dailymed.nlm.nih.gov, read Sep 27, 2026.
  14. To ensure safe and clinically appropriate prescribing, all GLP-1 medications require prior authorization and will only be authorized for uses approved by the FDA. southcarolinablues.com, read Sep 27, 2026.
  15. To give prior approval, we need to confirm two things: 1. that you’re using the drug to treat something we cover and 2. that your healthcare provider prescribes it in a medically appropriate way. fepblue.org, read Sep 27, 2026.
  16. Depending on the member’s benefit plan, weight loss drug coverage for a member newly prescribed a weight loss drug may only be available for treatment of Class III obesity (BMI ≥ 40), or for BMI ≥ 30 or BMI ≥ 27 with certain conditions. blueshieldca.com, read Sep 27, 2026.
  17. Many Aetna benefit plans specifically exclude coverage of weight reduction medications under the pharmacy benefit and/or under the health benefits plan. aetna.com, read Sep 27, 2026.
  18. You can choose to customize your benefits to include or exclude GLP-1 drug coverage for weight management. aetna.com, read Sep 27, 2026.
  19. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. dailymed.nlm.nih.gov, read Sep 27, 2026.
  20. discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide dailymed.nlm.nih.gov, read Sep 27, 2026.
  21. Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized dailymed.nlm.nih.gov, read Sep 27, 2026.
  22. A total of 9654 studies were identified, 365 read in full text and 11 RCTs were included. GLP1-RAs as an add-on showed a reduction in BMI compared to the control group, mean difference (95% CI), -1.38 (-2.39 to -0.38) kg/m2 (low certainty). pubmed.ncbi.nlm.nih.gov, read Sep 28, 2026.
  23. GLP-1-RAs are associated with modest short-term weight loss in women with PCOS and overweight or obesity. Evidence for benefits on metabolic, reproductive, or psychological outcomes remains uncertain due to low-quality data, and no studies have evaluated cost-effectiveness. pubmed.ncbi.nlm.nih.gov, read Sep 28, 2026.